Trillium Therapeutics shares soar on Pfizer’s $2.26B deal

Trillium Therapeutics shares soar on Pfizer’s $2.26B deal


Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.